Physician profile
Scott W Lundgren
NPI 1487092086
$179,410.35
in general payments reported to CMS, 2019-2025
17 companies · $63K in 2025
The $63K reported for 2025 was more than what 95% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,200 · 2021: $5,919 · 2022: $29K · 2023: $21K · 2024: $46K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $93K · Travel and Lodging: $27K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $92,783.50 |
| Travel and Lodging | $26,982.43 |
| Food and Beverage | $10,754.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $160,483.60 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Medtronic Vascular, INC. | $11,313.70 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,014.94 | 2020-2025 | |
| Cvrx, INC. | $1,980.94 | 2024-2025 | Barostim Neo System |
| Abiomed | $1,135.69 | 2023-2025 | Impella |
| One Lambda, INC. | $1,037.21 | 2024 | |
| Novartis Pharmaceuticals Corporation | $396.95 | 2020-2025 | |
| Paragonix Technologies, INC. | $297.20 | 2025 | |
| Impulse Dynamics (USA) INC. | $249.17 | 2023-2025 | Optimizer, Optimizer |
| United Therapeutics Corporation | $144.80 | 2022 | |
| Boston Scientific Corporation | $119.48 | 2023-2024 | Watchman Flx, Watchman Access System, Watchman |
| Vifor Pharma, INC. | $118.68 | 2019 | |
| Pfizer INC. | $41.50 | 2019-2022 | |
| Heartflow, INC. | $20.17 | 2025 | |
| Akcea Therapeutics, INC. | $19.80 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $18.46 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals Lp | $18.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lundgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.